08 August 2018
Visiongain has launched a new Pharmaceutical Report: Neuromodulation Devices Report 2017-2027: Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications
The report forecasts the neuromodulation devices market will multiply in revenues from 2017 to 2027. The pharmaceutical segment is evolving. Visiongain reports the strength of the neuromodulation devices market is its spinal cord stimulation segment, which generated revenues of $1.89bn. Growth in the market will be driven by the ageing population and the increasing prevalence of age-related conditions and chronic diseases. This will drive demand from both the developing and the developed world for neuromodulation devices. In addition, better access to healthcare and new diagnostic techniques has increased the number of people being identified with conditions such as chronic pain, and increase the number of patients receiving adequate treatment. Continuous research and development will lead to more applications being found for neuromodulation devices, with an increasing trend for more-personalised healthcare. All these factors combined will drive the growth of the neuromodulation devices industry through to 2027.
‘’Neuromodulation devices provide promising treatments for illnesses including chronic pain, epilepsy, Parkinson’s disease, depression and incontinence. The neuromodulation devices market is set to experience growth over the next 10 years, driven by the ageing population and the increasing prevalence of age-related conditions and chronic diseases and better access to healthcare. Continuous research and development will lead to more applications being found for neuromodulation devices, with an increasing trend for more-personalised healthcare.
The US will retain its position as market leader, emerging countries such as China and India will also contribute to the growth of the industry as they strive to provide better healthcare, thus increasing sales of neuromodulation devices.’’ – Medical Device Industry Analyst
The new report shows revenue forecasts to 2027 at overall world market, submarket and national level. It forecasts these world-level submarkets:
• Spinal Cord Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Deep Brain Stimulation
• Gastric Electric Stimulation
This investigation research, data and analyses covering activities of Medtronic, Boston Scientific
St Jude Medical (Subsidiary of Abbott Diagnostics), Cyberonics (Subsidiary of LivaNova).
Analyses cover R&D, Mergers and Acquisitions, and commercial news and predicts revenues to 2027 in leading regional markets. This includes the US, Japan, Germany, the UK, France, Italy, Spain (EU5 group), Brazil, Russia, India, China.
Neuromodulation Devices Report 2017-2027 adds to visiongain’s range of reports on industries and markets in healthcare. Together these studies cover medical devices, diagnostics and pharmaceuticals.
Leading companies featured in the report who are developing neuromodulation devices include Medtronic, Boston Scientific, St Jude Medical (Subsidiary of Abbott Diagnostics), Cyberonics (Subsidiary of LivaNova)
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
02 September 2021
As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.
24 August 2021
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
24 August 2021
Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.